Dear Editor, We read with great interest the study by Schmittinger et al. [1] hypothesizing that adverse cardiac events frequently occur during catecholamine vasopressor therapy and that catecholamine vasopressor support is associated with both morbidity and mortality. In this prospective observational study, 54 of 112 surgical intensive care unit patients with cardiovascular failure developed a total of 114 adverse cardiac events during catecholamine vasopressor therapy, an incidence of 48.2 % (95 % CI, 38.8-57.6 %). The two adverse cardiac events most frequently observed in this study were tachyarrhythmia and prolonged elevated heart rate, both of which were correlated with significant morbidity and mortality. Sepsis was observed in a total of 44 (39 %) patients. In the Patients and Methods section, the authors detailed that ''hydrocortisone (200-300 mg/ day) was added as a continuous infusion if escalating norepinephrine dose could not stabilize hemodynamic function.'' Unfortunately, we did not find any details about the dose, the duration and the weaning for hydrocortisone therapy in the results or in the discussion sections. There is still an ongoing debate about hydrocortisone therapy during septic shock: the CORTICUS study conducted by Sprung et al. [2] did not find a significant reduction in mortality in the hydrocortisone group, but Moreno et al.
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